Buy Semax nasal spray: what the bottle is and is not
Buy Semax nasal spray is how most people search for this compound, and the bottle that comes back is worth describing precisely. It is a peptide in solution in a pump dispenser, sold by a nootropic or supplement retailer, filled by whoever the retailer contracts with, and covered by whatever testing that retailer chooses to publish. It is not a pharmaceutical nasal spray and there is no approved one to sit beside it.
The compound itself is a synthetic heptapeptide, seven residues in the order Met-Glu-His-Phe-Pro-Gly-Pro, the ACTH(4-7) fragment with a Pro-Gly-Pro tail added to slow enzymatic breakdown. PubChem lists it as CID 9811102, formula C37H51N9O10S, molecular weight 813.9. It gets called a tuftsin analogue on a great many spray listings, and that is a different peptide: Selank, the other Russian heptapeptide, which has its own sequence and its own certificate. A listing that cannot keep the two apart is telling you something about how carefully it was written.
Nasal is the route this compound is associated with in nearly everything written about it, and a pump bottle asks nothing of a buyer that a sealed powder does. Those two facts together are most of the reason the spray became the consumer format here, rather than any regulatory or pharmaceutical decision, because no regulator and no pharmacist was involved in choosing it.
One supplier is linked on this page and we earn a commission if you buy through it, set out in full in our affiliate disclosure. That supplier sells the vial, not the spray, and the section below says plainly what that does and does not settle.
Why FDA wrote its concern route by route
The agency's note on this compound is short, and the phrase most pages drop is the one that matters most for a format question. Quoted in full from FDA's page on bulk drug substances that may present significant safety risks: "Compounded drugs containing semax (heptapeptide) may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities. FDA has no, or limited, safety-related information for proposed routes of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm if administered to humans."
Read the phrase "for certain routes of administration", twice in three sentences. The agency is not making a blanket statement about the molecule. It is saying that risk depends on how a preparation is given, and that it does not hold the safety information for the routes being proposed. A nasal spray is a route. Choosing it does not exempt a buyer from that sentence, and no part of the quotation says nasal is the safe option.
The mechanism named is worth keeping hold of too. Aggregation and peptide-related impurities are manufacturing and handling problems: peptide molecules clumping, and by-products of synthesis or degradation sitting alongside the intended one. Those are the things testing is designed to find. That is why the format matters commercially as well as clinically, because the two formats put the material through completely different handling before it reaches you.
The compounded nasal spray that would have to exist first
There is a version of this product that would answer most of the questions on this page, and it does not exist. A compounded nasal spray would be prepared by a licensed pharmacy against a prescriber's order, from a bulk substance the pharmacy is permitted to use, under a state board of pharmacy that can inspect it, with a labelled beyond-use date and a route back to the preparer if something went wrong.
Semax cannot reach that route. A pharmacy compounding under section 503A of the Federal Food, Drug and Cosmetic Act may work from a bulk drug substance only if it meets a United States Pharmacopeia or National Formulary monograph, is a component of an FDA-approved drug product, or appears on FDA's 503A bulks list. Semax satisfies none of the three, so no pharmacy has a lawful basis to fill a bottle of it whatever a prescriber wrote.
The bulks-list history is garbled almost everywhere, so here it is precisely. Semax was nominated for the list, was placed in category 2 under FDA's interim policies while the agency evaluated it, and the nomination was then withdrawn. It appears on no current category list. Category 2 today holds six substances and Semax is not among them. Nominated and withdrawn is accurate, category 2 is out of date, and banned is a word the agency did not use.
The result is that every Semax nasal spray on sale in the United States was filled outside that system. That is not an accusation about any particular seller. It is a description of the channel, and it is why our page on the legal position on Selank reaches the same structural conclusion for the compound sitting next to this one on the same shelves.
| Where it comes from | Who fills it | Oversight | Testing you can read before paying | Available |
|---|---|---|---|---|
| Approved nasal medicine | A manufacturer holding an approval | FDA review, inspections, recall path | An approved specification behind every batch | No, there is no approved Semax product |
| Compounded pharmacy nasal spray | A licensed pharmacy on a prescriber's order | State board of pharmacy, 503A conditions | Pharmacy records, labelled beyond-use date | No, the bulk substance fails the 503A test |
| Nootropic retail nasal spray | A retailer and its contract filler | None specific to the product | Whatever the seller chooses to publish | Yes, and this is what a search returns |
| Research lyophilised vial | A research-chemical supplier | None specific to the product | Batch certificate where the vendor publishes one | Yes, and it is not a spray |
The three things a Semax nasal spray could be in the United States, and what each one carries with it.
Semax nasal spray buy decisions: what a listing has to state
If you are going to buy a spray anyway, the listing has to answer a specific set of questions, and most do not. None of this requires trusting the seller, because all of it is either printed or absent.
Total peptide content and fill volume. A bottle priced with no stated milligram content cannot be compared with anything, including another spray. Without content and volume there is no concentration and no cost per milligram, only a price for an unspecified quantity of liquid.
What else is in the solution. A liquid sitting in a pump bottle at room temperature for weeks is a different preservation problem from a sealed lyophilised powder. A listing should say what the vehicle is and whether anything is in it to keep the contents stable and uncontaminated.
A batch number, and a certificate carrying it. Batch specific is the whole point. A generic product-line PDF, or a certificate emailed after payment for a lot you cannot match to the bottle in your hand, is documentation for somebody else's product.
Testing scope, not just a purity number. Purity says how much of the sample is the intended substance. It says nothing about endotoxin or microbial contamination, and those are the tests that speak to what FDA actually raised. For a liquid that has been filled, capped and shipped, the microbial question is more pressing rather than less.
Storage and shelf life once opened. A powder and an open pump bottle do not have the same clock. If the listing has no answer for the second one, it has not thought about the format it chose.
The vial the supplier we link actually sells
Ascension sells Semax as a 10 mg lyophilised vial. It is not a spray, and we would rather say that on a page about sprays than let the offer card imply otherwise. What the vial has is a four page combined certificate of analysis for batch 30-05260628, published before purchase.
The figures on it: purity 99.886 percent against a stated specification of greater than 98 percent, bacterial endotoxin by kinetic chromogenic LAL assay to USP Chapter 85 against an E. coli O111:B4 standard, reporting under 0.20 EU/mL against a 0.5 EU/mL acceptance limit, and a microbial sterility screen returning no growth. The commercial terms, checked on 21 August 2026, are $59.99 for the vial and $30.00 with the code PEPTIDEDECK, which is $3.00 per milligram.
The endotoxin and sterility lines are the unusual part, and they belong to a batch rather than to a product. The vendor's own February Semax certificate carries neither test, and its Selank listing shows the same February-to-June change. So a reader should open every certificate on a product page rather than only the one that is a clickable link. Our page on buying Selank as a nasal spray works through the same documents from the other side.
None of that makes a powder the right answer for somebody who wanted a spray. It makes the documentation checkable, which is a different and smaller claim. We give no preparation guidance here and none of the tests above describe a finished nasal preparation, because nobody has prepared one.
Where the format question lands
The honest summary is that this format choice is being made in a market with no reference product in it. With an approved nasal medicine, the manufacturer settled concentration, vehicle, preservation and shelf life, and a regulator reviewed the answer. Here nobody did, and two sellers can make completely different choices with equal confidence.
What remains under your control is which questions you require an answer to before paying: content and volume, contents of the solution, a batch number you can match, testing that covers contamination rather than purity alone, and storage after opening. For a route comparison on a compound where the clinic channel genuinely exists, our page on buying NAD+ as an injection shows what a format decision looks like when there is a regulated version to hold the unregulated one against. For Semax there is not, which is the point of this page.